The9-backed Nanyang Biologics to go public via $1.5B SPAC merger; shares up

* Nanyang Biologics, backed by The9 Limited (NASDAQ:NCTY [https://seekingalpha.com/symbol/NCTY]), will merge with SPAC RF Acquisition Corp II (NASDAQ:RFAI [https://seekingalpha.com/symbol/RFAI]) to become publicly listed on Nasdaq.
* The combined company will trade under the reserved ticker symbol “NYB” after closing.
* The deal values NYB at a $1.5B pre-transaction equity value.
* NYB shareholders, including The9, will roll over 100% of their equity and retain majority ownership and board control.
* The transaction has board approval and is expected to close in Q1 or Q2 2026.
* NYB will leverage its AI platform to speed up drug discovery and develop natural ingredient-based therapies.
* NCTY shares up 13% premarket on Thursday.
* Source: Press release [https://seekingalpha.com/pr/20252484-the9s-singapore-investee-nyb-announce-plan-to-go-nasdaq-via-us-1_5-billion-business]

MORE ON THE9 LIMITED, RF ACQUISITION CORP II

* The9 buys 51% of gaming JV for $16.2M [https://seekingalpha.com/news/4496424-the9-buys-51-of-gaming-jv-for-162m]
* Financial information for The9 Limited [https://seekingalpha.com/symbol/NCTY/income-statement]
* Financial information for RF Acquisition Corp II [https://seekingalpha.com/symbol/RFAI/income-statement]